2B70:F:F-iShares NASDAQ US Biotechnology UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 5.565

Change

-0.05 (-0.93)%

Market Cap

USD 0.52B

Volume

563.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.03 (-0.10%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.09 (-0.18%)

USD 115.04B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.01 (+0.05%)

USD 83.57B
SXR8:F iShares Core S&P 500 UCITS ETF..

-2.75 (-0.55%)

USD 80.45B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.01 (+0.01%)

USD 76.57B
EUNL:F iShares Core MSCI World UCITS ..

-0.25 (-0.28%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

-1.60 (-0.70%)

USD 58.19B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 56.18B
VUSA:F Vanguard Funds Public Limited ..

-0.51 (-0.57%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.46 (-0.52%)

USD 49.95B

ETFs Containing 2B70:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.33% 28% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.33% 26% F 42% F
Trailing 12 Months  
Capital Gain 0.09% 34% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.09% 32% F 48% F
Trailing 5 Years  
Capital Gain 34.58% 62% D 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.58% 62% D 52% F
Average Annual (5 Year Horizon)  
Capital Gain 6.94% 75% C 71% C-
Dividend Return 6.94% 74% C 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.87% 38% F 68% D+
Risk Adjusted Return 46.70% 76% C+ 78% C+
Market Capitalization 0.52B 62% D 50% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.